C.R. Jackson
Contributor since: 2012
Latest Articles
Volatile Versartis May Have Significant Upside
These 2 Stocks Could Be Winners Because Plenty Of People Want To Look Younger
Why Have Revance Therapeutics Shares More Than Doubled Since The February IPO?
TetraLogic Pharmaceuticals And The Chatter About A Cure For Cancer
Biopharma Bottomfishing: Are Any Of These 3 Stocks Under $9 A Good Catch?
Evoke Pharma Moves Full Speed Ahead
Five Prime Therapeutics: A Small Cap With A Big Protein Therapeutic Platform
Tetraphase Pharmaceuticals: A Small Cap With Big Potential
NuPathe Takes Investors Down A Bumpy Road
Does Conatus Pharmaceuticals Have A Winner With Emricasan?
Is Biodel A Buy Or Sell?
How High Will Bluebird Bio Fly?
Does Esperion Therapeutics Have A Blockbuster With ETC-1002?
Why Is BioCryst Pharmaceuticals At 52 Week High Levels?
Innovative KaloBios Pharmacuticals Could Be A Lucrative Buy
Will Coronado Biosciences Revolutionize Medicine?
What Is On The Horizon For XOMA?
Will Big Changes At Apricus Biosciences Make It A Winning Stock?
Near A 52-Week Low, Is Ventrus Biosciences A Good Buy?
Can Cempra Beat The Superbugs?
Near A 52-Week Low, Is OncoGenex Pharmaceuticals A Buy?
Why Did Immunotherapy Pioneer NewLink Genetics Reach A 52-Week High?
Avanir Pharmaceuticals Builds A Pipeline In A Pill
3 Innovative Biotech Companies With Promising Cancer Therapies
Part 3: Will Array BioPharma Become A Late Stage Biopharmaceutical Company?
Part 2: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
Is It Time To Give Up On Dendreon?
Why Did Pain Therapeutics Increase Over 25%?
Questcor Pharmaceuticals: How Can Such A Profitable Company Be So Risky?
Why Did Vanda Pharmaceuticals Hit A 52-Week High?
2 High Risk Biotech Stocks Under $2 That Could Yield A High Reward